Patients received a symptom-triggered Clinical Institute Withdrawal Assessment protocol with lorazepam and were randomized to dexmedetomidine 1.2 g/kg/hr ( high dose ) , 0.4 g/kg/hr ( low dose ) , or placebo as adjunctive therapy for up to 5 days or resolution of withdrawal symptoms .